Last 12 months
Inside the activity.
0 purchase rows · 93 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 6 |
| Dec 2025 | 0 | 16 |
| Jan 2026 | 0 | 2 |
| Feb 2026 | 0 | 49 |
| Mar 2026 | 0 | 5 |
| Apr 2026 | 0 | 1 |
| May 2026 | 0 | 6 |
| Jun 2026 | 0 | 5 |
| Jul 2026 | 0 | 3 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 05, 2020 Filed Feb 7, 2020 21:28 UTC |
Tatsis OuraniaSVP, CRO
|
GrantCommon Stock | 3,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-007525 · doc4.xml · nonDerivative · entry 1 Tatsis Ourania · CIK 0001789815 · SVP, CRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,752 F1 · shares: Represents earned performance shares with respect to a performance stock unit award granted on 02/06/2019 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/05/2020. The earned performance shares will vest in installments beginning on 2/24/2020. Read SEC document |
| February 05, 2020 Filed Feb 7, 2020 21:30 UTC |
WAGNER CHARLES F JREVP and CFO
|
GrantCommon Stock | 10,323 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-007528 · doc4.xml · nonDerivative · entry 2 WAGNER CHARLES F JR · CIK 0001223348 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,816 F2 · shares: Restricted stock unit award that vests in installments beginning on 02/10/2021. Read SEC document |
| February 05, 2020 Filed Feb 7, 2020 21:30 UTC |
WAGNER CHARLES F JREVP and CFO
|
GrantCommon Stock | 3,698 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-007528 · doc4.xml · nonDerivative · entry 1 WAGNER CHARLES F JR · CIK 0001223348 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,493 F1 · shares: Represents earned performance shares with respect to a performance stock unit award granted on 04/10/2019 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/05/2020. The earned performance shares will vest in installments beginning on 2/24/2020. Read SEC document |
| February 05, 2020 Filed Feb 14, 2020 22:01 UTC Amendment |
LEIDEN JEFFREY MDirector · CEO & President
|
GrantCommon Stock | 31,462 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-009734 · doc4a.xml · nonDerivative · entry 3 LEIDEN JEFFREY M · CIK 0001242825 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 216,818 F1 · date: This Amendment to Form 4 is filed solely for the purpose of correcting a clerical error in the transaction date reported in Table I, column 2 on the Form 4 filed on February 7, 2020. The correct transaction date is February 5, 2020 as was reflected in Item 3 of the original filing. F4 · shares: Restricted stock unit award that will vest pursuant to his employment agreement upon Dr. Leiden's transition from CEO. Read SEC document |
| February 05, 2020 Filed Feb 14, 2020 22:01 UTC Amendment |
LEIDEN JEFFREY MDirector · CEO & President
|
GrantCommon Stock | 28,444 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-009734 · doc4a.xml · nonDerivative · entry 2 LEIDEN JEFFREY M · CIK 0001242825 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 185,356 F1 · date: This Amendment to Form 4 is filed solely for the purpose of correcting a clerical error in the transaction date reported in Table I, column 2 on the Form 4 filed on February 7, 2020. The correct transaction date is February 5, 2020 as was reflected in Item 3 of the original filing. F3 · shares: Represents earned performance shares with respect to a performance stock unit award granted on 02/06/2019 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/05/2020 and the shares will vest in installments beginning on 02/24/2020. Read SEC document |
| February 05, 2020 Filed Feb 14, 2020 22:01 UTC Amendment |
LEIDEN JEFFREY MDirector · CEO & President
|
GrantCommon Stock | 50,566 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-009734 · doc4a.xml · nonDerivative · entry 1 LEIDEN JEFFREY M · CIK 0001242825 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 156,912 F1 · date: This Amendment to Form 4 is filed solely for the purpose of correcting a clerical error in the transaction date reported in Table I, column 2 on the Form 4 filed on February 7, 2020. The correct transaction date is February 5, 2020 as was reflected in Item 3 of the original filing. F2 · shares: Represents earned performance shares with respect to a performance stock unit award granted on 02/03/2017 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/05/2020 and the shares will vest on 02/10/2020. Read SEC document |
| February 04, 2020 Filed Feb 6, 2020 21:06 UTC |
Lee YuchunDirector
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 3,028 | $0.00 Strike: $57.27 | $0.00 |
DisclosureSEC source: 0001209191-20-007151 · doc4.xml · derivative · entry 13 Lee Yuchun · CIK 0001334365 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,306 Underlying: Common Stock · 3,028 shares Expires 2022-09-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F13 · derivative.exercise_date: Fully vested. Read SEC document |
| February 04, 2020 Filed Feb 6, 2020 21:06 UTC |
Lee YuchunDirector
|
SaleCommon Stock | 112 | $241.01 | $26,993.12 |
DisclosureSEC source: 0001209191-20-007151 · doc4.xml · nonDerivative · entry 7 Lee Yuchun · CIK 0001334365 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,875 F1 · kind: Transaction made pursuant to Mr. Lee's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Lee undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F8 · price: Open market sales reported on this line occurred at a weighted average price of $241.01 (range $240.96 to $241.06). Read SEC document |
| February 04, 2020 Filed Feb 6, 2020 21:06 UTC |
Lee YuchunDirector
|
SaleCommon Stock | 1,026 | $239.81 | $246,045.06 |
DisclosureSEC source: 0001209191-20-007151 · doc4.xml · nonDerivative · entry 6 Lee Yuchun · CIK 0001334365 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,987 F1 · kind: Transaction made pursuant to Mr. Lee's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Lee undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F7 · price: Open market sales reported on this line occurred at a weighted average price of $239.81 (range $239.48 to $240.14). Read SEC document |
| February 04, 2020 Filed Feb 6, 2020 21:06 UTC |
Lee YuchunDirector
|
SaleCommon Stock | 353 | $238.94 | $84,345.82 |
DisclosureSEC source: 0001209191-20-007151 · doc4.xml · nonDerivative · entry 5 Lee Yuchun · CIK 0001334365 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,013 F1 · kind: Transaction made pursuant to Mr. Lee's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Lee undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F6 · price: Open market sales reported on this line occurred at a weighted average price of $238.94 (range $238.46 to $239.45). Read SEC document |
| February 04, 2020 Filed Feb 6, 2020 21:06 UTC |
Lee YuchunDirector
|
SaleCommon Stock | 233 | $236.99 | $55,218.67 |
DisclosureSEC source: 0001209191-20-007151 · doc4.xml · nonDerivative · entry 4 Lee Yuchun · CIK 0001334365 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,366 F1 · kind: Transaction made pursuant to Mr. Lee's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Lee undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5 · price: Open market sales reported on this line occurred at a weighted average price of $236.99 (range $236.77 to $237.53). Read SEC document |
| February 04, 2020 Filed Feb 6, 2020 21:06 UTC |
Lee YuchunDirector
|
SaleCommon Stock | 161 | $236.19 | $38,026.59 |
DisclosureSEC source: 0001209191-20-007151 · doc4.xml · nonDerivative · entry 3 Lee Yuchun · CIK 0001334365 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,599 F1 · kind: Transaction made pursuant to Mr. Lee's company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $235.15 (range $234.86 to $235.50). F4 · price: Open market sales reported on this line occurred at a weighted average price of $236.19 (range $235.90 to $236.44). Read SEC document |
| February 04, 2020 Filed Feb 6, 2020 21:06 UTC |
Lee YuchunDirector
|
SaleCommon Stock | 115 | $235.15 | $27,042.25 |
DisclosureSEC source: 0001209191-20-007151 · doc4.xml · nonDerivative · entry 2 Lee Yuchun · CIK 0001334365 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,760 F1 · kind: Transaction made pursuant to Mr. Lee's company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $235.15 (range $234.86 to $235.50). F3 · price: Mr. Lee undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| February 04, 2020 Filed Feb 6, 2020 21:06 UTC |
Lee YuchunDirector
|
Exercise / conversionCommon Stock | 3,028 | $57.27 | $173,413.56 |
DisclosureSEC source: 0001209191-20-007151 · doc4.xml · nonDerivative · entry 1 Lee Yuchun · CIK 0001334365 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,875 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 03, 2020 Filed Feb 4, 2020 21:10 UTC |
Arbuckle Stuart AEVP, Chief Commercial Officer
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 1,554 | $0.00 Strike: $86.52 | $0.00 |
DisclosureSEC source: 0001209191-20-006279 · doc4.xml · derivative · entry 13 Arbuckle Stuart A · CIK 0001557290 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,213 Underlying: Common Stock · 1,554 shares Expires 2027-02-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F10 · derivative.exercise_date: The option vests in 16 quarterly installments from 02/03/2017. Read SEC document |
| February 03, 2020 Filed Feb 4, 2020 21:10 UTC |
Arbuckle Stuart AEVP, Chief Commercial Officer
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 2,156 | $0.00 Strike: $91.05 | $0.00 |
DisclosureSEC source: 0001209191-20-006279 · doc4.xml · derivative · entry 12 Arbuckle Stuart A · CIK 0001557290 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,156 shares Expires 2026-02-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_date: Fully vested. Read SEC document |
| February 03, 2020 Filed Feb 4, 2020 21:10 UTC |
Arbuckle Stuart AEVP, Chief Commercial Officer
|
SaleCommon Stock | 540 | $232.71 | $125,663.40 |
DisclosureSEC source: 0001209191-20-006279 · doc4.xml · nonDerivative · entry 9 Arbuckle Stuart A · CIK 0001557290 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,240 F1 · kind: Transaction made pursuant to Mr. Arbuckle's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Arbuckle undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F7 · price: Open market sales reported on this line occurred at a weighted average price of $232.71 (range $232.50 to $232.94). Read SEC document |
| February 03, 2020 Filed Feb 4, 2020 21:10 UTC |
Arbuckle Stuart AEVP, Chief Commercial Officer
|
SaleCommon Stock | 900 | $231.87 | $208,683.00 |
DisclosureSEC source: 0001209191-20-006279 · doc4.xml · nonDerivative · entry 8 Arbuckle Stuart A · CIK 0001557290 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,780 F1 · kind: Transaction made pursuant to Mr. Arbuckle's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Arbuckle undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F6 · price: Open market sales reported on this line occurred at a weighted average price of $231.87 (range $231.50 to $232.44). Read SEC document |
| February 03, 2020 Filed Feb 4, 2020 21:10 UTC |
Arbuckle Stuart AEVP, Chief Commercial Officer
|
SaleCommon Stock | 1,300 | $231.16 | $300,508.00 |
DisclosureSEC source: 0001209191-20-006279 · doc4.xml · nonDerivative · entry 7 Arbuckle Stuart A · CIK 0001557290 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,680 F1 · kind: Transaction made pursuant to Mr. Arbuckle's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Arbuckle undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5 · price: Open market sales reported on this line occurred at a weighted average price of $231.16 (range $230.48 to $231.47). Read SEC document |
| February 03, 2020 Filed Feb 4, 2020 21:10 UTC |
Arbuckle Stuart AEVP, Chief Commercial Officer
|
SaleCommon Stock | 530 | $229.99 | $121,894.70 |
DisclosureSEC source: 0001209191-20-006279 · doc4.xml · nonDerivative · entry 6 Arbuckle Stuart A · CIK 0001557290 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,980 F1 · kind: Transaction made pursuant to Mr. Arbuckle's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Arbuckle undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $229.99 (range $229.48 to $230.46). Read SEC document |
| February 03, 2020 Filed Feb 4, 2020 21:10 UTC |
Arbuckle Stuart AEVP, Chief Commercial Officer
|
SaleCommon Stock | 440 | $228.90 | $100,716.00 |
DisclosureSEC source: 0001209191-20-006279 · doc4.xml · nonDerivative · entry 5 Arbuckle Stuart A · CIK 0001557290 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,510 F1 · kind: Transaction made pursuant to Mr. Arbuckle's company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $228.90 (range $228.37 to $229.11). F3 · price: Mr. Arbuckle undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| February 03, 2020 Filed Feb 4, 2020 21:10 UTC |
Arbuckle Stuart AEVP, Chief Commercial Officer
|
Exercise / conversionCommon Stock | 1,554 | $86.52 | $134,452.08 |
DisclosureSEC source: 0001209191-20-006279 · doc4.xml · nonDerivative · entry 4 Arbuckle Stuart A · CIK 0001557290 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,950 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 03, 2020 Filed Feb 4, 2020 21:10 UTC |
Arbuckle Stuart AEVP, Chief Commercial Officer
|
Exercise / conversionCommon Stock | 2,156 | $91.05 | $196,303.80 |
DisclosureSEC source: 0001209191-20-006279 · doc4.xml · nonDerivative · entry 3 Arbuckle Stuart A · CIK 0001557290 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,396 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 03, 2020 Filed Feb 4, 2020 21:11 UTC |
Lee YuchunDirector
|
SaleCommon Stock | 200 | $232.69 | $46,538.00 |
DisclosureSEC source: 0001209191-20-006284 · doc4.xml · nonDerivative · entry 11 Lee Yuchun · CIK 0001334365 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 847 F1 · kind: Transaction made pursuant to Mr. Lee's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Lee undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F12 · price: Open market sales reported on this line occurred at a weighted average price of $232.69 (range $232.67 to $232.70). Read SEC document |
| February 03, 2020 Filed Feb 4, 2020 21:11 UTC |
Lee YuchunDirector
|
SaleCommon Stock | 956 | $231.70 | $221,505.20 |
DisclosureSEC source: 0001209191-20-006284 · doc4.xml · nonDerivative · entry 10 Lee Yuchun · CIK 0001334365 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,047 F1 · kind: Transaction made pursuant to Mr. Lee's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Lee undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F11 · price: Open market sales reported on this line occurred at a weighted average price of $231.70 (range $231.31 to $232.28). Read SEC document |
| February 03, 2020 Filed Feb 4, 2020 21:11 UTC |
Lee YuchunDirector
|
SaleCommon Stock | 421 | $230.69 | $97,120.49 |
DisclosureSEC source: 0001209191-20-006284 · doc4.xml · nonDerivative · entry 9 Lee Yuchun · CIK 0001334365 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,003 F1 · kind: Transaction made pursuant to Mr. Lee's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Lee undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F10 · price: Open market sales reported on this line occurred at a weighted average price of $230.69 (range $230.26 to $231.19). Read SEC document |
| February 03, 2020 Filed Feb 4, 2020 21:11 UTC |
Lee YuchunDirector
|
SaleCommon Stock | 423 | $229.39 | $97,031.97 |
DisclosureSEC source: 0001209191-20-006284 · doc4.xml · nonDerivative · entry 8 Lee Yuchun · CIK 0001334365 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,424 F1 · kind: Transaction made pursuant to Mr. Lee's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Lee undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F9 · price: Open market sales reported on this line occurred at a weighted average price of $229.39 (range $229.16 to $229.93). Read SEC document |
| February 03, 2020 Filed Feb 4, 2020 21:13 UTC |
Parini MichaelEVP, CL&AO
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 2,330 | $0.00 Strike: $86.52 | $0.00 |
DisclosureSEC source: 0001209191-20-006289 · doc4.xml · derivative · entry 11 Parini Michael · CIK 0001661567 · EVP, CL&AO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,320 Underlying: Common Stock · 2,330 shares Expires 2027-02-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_date: The option vests in 16 quarterly installments from 02/03/2017. Read SEC document |
| February 03, 2020 Filed Feb 4, 2020 21:13 UTC |
Parini MichaelEVP, CL&AO
|
SaleCommon Stock | 400 | $233.03 | $93,212.00 |
DisclosureSEC source: 0001209191-20-006289 · doc4.xml · nonDerivative · entry 9 Parini Michael · CIK 0001661567 · EVP, CL&AO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,553 F1 · kind: Transaction made pursuant to Mr. Parini's company-approved trading plan under Rule 10b5-1. F3 · price: Mr. Parini undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F7 · price: Open market sales reported on this line occurred at a weighted average price of $233.03 (range $232.95 to $233.26). Read SEC document |
| February 03, 2020 Filed Feb 4, 2020 21:13 UTC |
Parini MichaelEVP, CL&AO
|
SaleCommon Stock | 1,500 | $231.84 | $347,760.00 |
DisclosureSEC source: 0001209191-20-006289 · doc4.xml · nonDerivative · entry 8 Parini Michael · CIK 0001661567 · EVP, CL&AO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,953 F1 · kind: Transaction made pursuant to Mr. Parini's company-approved trading plan under Rule 10b5-1. F3 · price: Mr. Parini undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F6 · price: Open market sales reported on this line occurred at a weighted average price of $231.84 (range $231.58 to $232.44). Read SEC document |
| February 03, 2020 Filed Feb 4, 2020 21:13 UTC |
Parini MichaelEVP, CL&AO
|
SaleCommon Stock | 1,350 | $231.20 | $312,120.00 |
DisclosureSEC source: 0001209191-20-006289 · doc4.xml · nonDerivative · entry 7 Parini Michael · CIK 0001661567 · EVP, CL&AO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,453 F1 · kind: Transaction made pursuant to Mr. Parini's company-approved trading plan under Rule 10b5-1. F3 · price: Mr. Parini undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5 · price: Open market sales reported on this line occurred at a weighted average price of $231.20 (range $230.53 to $231.52). Read SEC document |
| February 03, 2020 Filed Feb 4, 2020 21:13 UTC |
Parini MichaelEVP, CL&AO
|
SaleCommon Stock | 612 | $230.02 | $140,772.24 |
DisclosureSEC source: 0001209191-20-006289 · doc4.xml · nonDerivative · entry 6 Parini Michael · CIK 0001661567 · EVP, CL&AO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,803 F1 · kind: Transaction made pursuant to Mr. Parini's company-approved trading plan under Rule 10b5-1. F3 · price: Mr. Parini undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $230.02 (range $229.48 to $230.47). Read SEC document |
| February 03, 2020 Filed Feb 4, 2020 21:13 UTC |
Parini MichaelEVP, CL&AO
|
SaleCommon Stock | 574 | $229.07 | $131,486.18 |
DisclosureSEC source: 0001209191-20-006289 · doc4.xml · nonDerivative · entry 5 Parini Michael · CIK 0001661567 · EVP, CL&AO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,415 F1 · kind: Transaction made pursuant to Mr. Parini's company-approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $229.07 (range $228.44 to $229.42). F3 · price: Mr. Parini undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| February 03, 2020 Filed Feb 4, 2020 21:13 UTC |
Parini MichaelEVP, CL&AO
|
Exercise / conversionCommon Stock | 2,330 | $86.52 | $201,591.60 |
DisclosureSEC source: 0001209191-20-006289 · doc4.xml · nonDerivative · entry 4 Parini Michael · CIK 0001661567 · EVP, CL&AO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,989 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 03, 2020 Filed Feb 5, 2020 21:50 UTC |
ALTSHULER DAVIDEVP, Global Research and CSO
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 2,330 | $0.00 Strike: $86.52 | $0.00 |
DisclosureSEC source: 0001209191-20-006950 · doc4.xml · derivative · entry 8 ALTSHULER DAVID · CIK 0001550395 · EVP, Global Research and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,320 Underlying: Common Stock · 2,330 shares Expires 2027-02-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_date: The option vests in 16 quarterly installments from 02/03/2017. Read SEC document |
| February 03, 2020 Filed Feb 5, 2020 21:50 UTC |
ALTSHULER DAVIDEVP, Global Research and CSO
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 1,796 | $0.00 Strike: $91.05 | $0.00 |
DisclosureSEC source: 0001209191-20-006950 · doc4.xml · derivative · entry 7 ALTSHULER DAVID · CIK 0001550395 · EVP, Global Research and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,796 shares Expires 2026-02-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: Fully vested. Read SEC document |
| February 03, 2020 Filed Feb 5, 2020 21:50 UTC |
ALTSHULER DAVIDEVP, Global Research and CSO
|
SaleCommon Stock | 470 | $232.88 | $109,453.60 |
DisclosureSEC source: 0001209191-20-006950 · doc4.xml · nonDerivative · entry 6 ALTSHULER DAVID · CIK 0001550395 · EVP, Global Research and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,553 F1 · kind: Transaction made pursuant to Dr. Altshuler's company approved trading plan under Rule 10b5-1. F3 · price: Dr. Altshuler undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F6 · price: Open market sales reported on this line occurred at a weighted average price of $232.88 (range $232.43 to $233.16). Read SEC document |
| February 03, 2020 Filed Feb 5, 2020 21:50 UTC |
ALTSHULER DAVIDEVP, Global Research and CSO
|
SaleCommon Stock | 2,122 | $231.67 | $491,603.74 |
DisclosureSEC source: 0001209191-20-006950 · doc4.xml · nonDerivative · entry 5 ALTSHULER DAVID · CIK 0001550395 · EVP, Global Research and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,023 F1 · kind: Transaction made pursuant to Dr. Altshuler's company approved trading plan under Rule 10b5-1. F3 · price: Dr. Altshuler undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5 · price: Open market sales reported on this line occurred at a weighted average price of $231.67 (range $231.31 to $232.28). Read SEC document |
| February 03, 2020 Filed Feb 5, 2020 21:50 UTC |
ALTSHULER DAVIDEVP, Global Research and CSO
|
SaleCommon Stock | 785 | $230.60 | $181,021.00 |
DisclosureSEC source: 0001209191-20-006950 · doc4.xml · nonDerivative · entry 4 ALTSHULER DAVID · CIK 0001550395 · EVP, Global Research and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,145 F1 · kind: Transaction made pursuant to Dr. Altshuler's company approved trading plan under Rule 10b5-1. F3 · price: Dr. Altshuler undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $230.60 (range $230.30 to $231.11). Read SEC document |
| February 03, 2020 Filed Feb 5, 2020 21:50 UTC |
ALTSHULER DAVIDEVP, Global Research and CSO
|
SaleCommon Stock | 749 | $229.35 | $171,783.15 |
DisclosureSEC source: 0001209191-20-006950 · doc4.xml · nonDerivative · entry 3 ALTSHULER DAVID · CIK 0001550395 · EVP, Global Research and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,930 F1 · kind: Transaction made pursuant to Dr. Altshuler's company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $229.35 (range $229.00 to $229.93). F3 · price: Dr. Altshuler undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| February 03, 2020 Filed Feb 5, 2020 21:50 UTC |
ALTSHULER DAVIDEVP, Global Research and CSO
|
Exercise / conversionCommon Stock | 2,330 | $86.52 | $201,591.60 |
DisclosureSEC source: 0001209191-20-006950 · doc4.xml · nonDerivative · entry 2 ALTSHULER DAVID · CIK 0001550395 · EVP, Global Research and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,679 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 03, 2020 Filed Feb 5, 2020 21:50 UTC |
ALTSHULER DAVIDEVP, Global Research and CSO
|
Exercise / conversionCommon Stock | 1,796 | $91.05 | $163,525.80 |
DisclosureSEC source: 0001209191-20-006950 · doc4.xml · nonDerivative · entry 1 ALTSHULER DAVID · CIK 0001550395 · EVP, Global Research and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,349 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 03, 2020 Filed Feb 5, 2020 21:51 UTC |
Sachdev AmitEVP, Chief Patient Officer
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 1,941 | $0.00 Strike: $86.52 | $0.00 |
DisclosureSEC source: 0001209191-20-006956 · doc4.xml · derivative · entry 11 Sachdev Amit · CIK 0001406338 · EVP, Chief Patient Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,767 Underlying: Common Stock · 1,941 shares Expires 2027-02-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_date: The option vests in 16 quarterly installments from 02/03/2017. Read SEC document |
| February 03, 2020 Filed Feb 5, 2020 21:51 UTC |
Sachdev AmitEVP, Chief Patient Officer
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 2,156 | $0.00 Strike: $91.05 | $0.00 |
DisclosureSEC source: 0001209191-20-006956 · doc4.xml · derivative · entry 10 Sachdev Amit · CIK 0001406338 · EVP, Chief Patient Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,156 shares Expires 2026-02-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_date: Fully vested. Read SEC document |
| February 03, 2020 Filed Feb 5, 2020 21:51 UTC |
Sachdev AmitEVP, Chief Patient Officer
|
SaleCommon Stock | 400 | $232.87 | $93,148.00 |
DisclosureSEC source: 0001209191-20-006956 · doc4.xml · nonDerivative · entry 7 Sachdev Amit · CIK 0001406338 · EVP, Chief Patient Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,190 F1 · kind: Transaction made pursuant to Mr. Sachdev's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Sachdev undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F7 · price: Open market sales reported on this line occurred at a weighted average price of $232.87 (range $232.67 to $233.31). Read SEC document |
| February 03, 2020 Filed Feb 5, 2020 21:51 UTC |
Sachdev AmitEVP, Chief Patient Officer
|
SaleCommon Stock | 1,177 | $231.92 | $272,969.84 |
DisclosureSEC source: 0001209191-20-006956 · doc4.xml · nonDerivative · entry 6 Sachdev Amit · CIK 0001406338 · EVP, Chief Patient Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,590 F1 · kind: Transaction made pursuant to Mr. Sachdev's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Sachdev undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F6 · price: Open market sales reported on this line occurred at a weighted average price of $231.92 (range $231.54 to $232.50). Read SEC document |
| February 03, 2020 Filed Feb 5, 2020 21:51 UTC |
Sachdev AmitEVP, Chief Patient Officer
|
SaleCommon Stock | 1,306 | $231.25 | $302,012.50 |
DisclosureSEC source: 0001209191-20-006956 · doc4.xml · nonDerivative · entry 5 Sachdev Amit · CIK 0001406338 · EVP, Chief Patient Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,767 F1 · kind: Transaction made pursuant to Mr. Sachdev's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Sachdev undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5 · price: Open market sales reported on this line occurred at a weighted average price of $231.25 (range $230.53 to $231.50). Read SEC document |
| February 03, 2020 Filed Feb 5, 2020 21:51 UTC |
Sachdev AmitEVP, Chief Patient Officer
|
SaleCommon Stock | 714 | $230.07 | $164,269.98 |
DisclosureSEC source: 0001209191-20-006956 · doc4.xml · nonDerivative · entry 4 Sachdev Amit · CIK 0001406338 · EVP, Chief Patient Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,073 F1 · kind: Transaction made pursuant to Mr. Sachdev's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Sachdev undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $230.07 (range $229.48 to $230.47). Read SEC document |
| February 03, 2020 Filed Feb 5, 2020 21:51 UTC |
Sachdev AmitEVP, Chief Patient Officer
|
SaleCommon Stock | 500 | $228.89 | $114,445.00 |
DisclosureSEC source: 0001209191-20-006956 · doc4.xml · nonDerivative · entry 3 Sachdev Amit · CIK 0001406338 · EVP, Chief Patient Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,787 F1 · kind: Transaction made pursuant to Mr. Sachdev's company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $228.89 (range $228.37 to $229.12). F3 · price: Mr. Sachdev undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| February 03, 2020 Filed Feb 5, 2020 21:51 UTC |
Sachdev AmitEVP, Chief Patient Officer
|
Exercise / conversionCommon Stock | 1,941 | $86.52 | $167,935.32 |
DisclosureSEC source: 0001209191-20-006956 · doc4.xml · nonDerivative · entry 2 Sachdev Amit · CIK 0001406338 · EVP, Chief Patient Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,287 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.